Arthur Fratamico, Radiant Biotherapeutics CEO
September 11, 2024 07:00 AM EDT
Financing
Startups

Ra­di­ant Bio snags $35M for an­ti­body plat­form, with GSK and Re­gen­eron part­ner­ships

Kyle LaHucik

Senior Reporter

A drug de­vel­op­er aim­ing to cre­ate more po­tent, ef­fec­tive an­ti­bod­ies un­veiled a $35 mil­lion Se­ries A on Wednes­day with the sup­port of the Bill …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times